Cancer bio-immunotherapy XVII annual NIBIT (Italian Network for Tumor Biotherapy) meeting, October 11–13 2019, Verona, Italy.

The tumor microenvironment (TME) has a central role in restraining tumor growth, and a deep understanding of the interplay between cancer cells and their local environment is relevant to designing immunotherapies that fit each tumor best. Today, treatment allocation of PDAC patient is currently based on clinical, biochemical, and radiologic features but, to reach a personalized treatment, it is mandatory to identify new tools to predict tumor response and develop a more effective patient treatment. Activation of tumor-specific CD8 T cells that mediate regression of the irradiated tumor as well as a non-irradiated synchronous tumor (abscopal effect) is seen only when radiation is combined with CTLA-4 blockade, whereas each treatment alone was ineffective, demonstrating a therapeutic synergy of radiation and CTLA4 blockade. Keywords: Immunotherapy; Cancer vaccines; Checkpoint blockade agents; Adoptive immunotherapy; Targeted therapies; NIBIT EN Immunotherapy Cancer vaccines Checkpoint blockade agents Adoptive immunotherapy Targeted therapies NIBIT 1777 1786 10 06/15/22 20220701 NES 220701 Introduction Oncology embrace Immunology: the way forward captioned the XVII international meeting of the Italian Network for Tumor Biotherapy (NIBIT) held in Verona on October 11-13, 2019. [Extracted from the article]